Skip to main content
Mayne Pharma shares rise 81% on A$604m takeover
Image for illustrative purposes only. Not a real photo.

Mayne Pharma shares rise 81% on A$604m takeover

By

Key points

  • Mayne Pharma (ASX:MYX) has agreed to be acquired by Hungarian drugmaker Gedeon Richter for A$6.40 cash per share, valuing its equity at about A$604 million.
  • The offer is a 99.4% premium to Mayne’s closing price on 16 November and a 124% premium to its 30-day volume-weighted average price.
  • Mayne said the deal follows its agreed sale of its International business, which would leave a company focused on the United States.

Mayne Pharma (ASX:MYX) has agreed to a takeover by Hungarian drugmaker Gedeon Richter (BPSE:RICHTER) at A$6.40 cash per share, valuing Mayne’s equity at about A$604 million.

The offer is 99.4% above Mayne’s closing price on 16 November and 124% above its 30-day volume-weighted average price.

“The Board’s priority throughout has been to maximise value and certainty for all shareholders,” said Mayne Pharma Chair Professor Bruce Robinson.

The deal needs foreign investment and US antitrust approval, shareholder and court approval, and completion of Mayne’s sale of its International business to Evaris Pharma, with a A$6 million break fee payable by either side.

Mayne expects shareholders to vote in late January 2027 and the deal to be implemented in mid-to-late March 2027; following the announcement the Mayne Pharma share price was up at A$5.81.

Mayne’s board unanimously recommends the deal, subject to no superior proposal and an independent expert finding it in shareholders’ best interests, and its three largest shareholders, holding 22.14%, intend to vote in favour.

The agreement follows a failed A$7.40-a-share scheme with US-based Cosette Pharmaceuticals, signed in February 2025, which Mayne moved to terminate after Cosette sought to withdraw.


Frequently asked questions